Tandem Diabetes Care (TNDM) Competitors

iRhythm Technologies (NASDAQ:IRTC) and Tandem Diabetes Care (NASDAQ:TNDM) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Do analysts recommend IRTC or TNDM?

iRhythm Technologies presently has a consensus target price of $134.00, indicating a potential upside of 51.91%. Tandem Diabetes Care has a consensus target price of $50.58, indicating a potential downside of 1.26%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tandem Diabetes Care	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Is IRTC or TNDM more profitable?

Tandem Diabetes Care has a net margin of -18.37% compared to Tandem Diabetes Care's net margin of -25.33%. iRhythm Technologies' return on equity of -34.38% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-25.33%	-69.87%	-23.50%
Tandem Diabetes Care	-18.37%	-34.38%	-10.91%

Which has more volatility and risk, IRTC or TNDM?

iRhythm Technologies has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Does the media favor IRTC or TNDM?

In the previous week, Tandem Diabetes Care had 10 more articles in the media than iRhythm Technologies. MarketBeat recorded 14 mentions for Tandem Diabetes Care and 4 mentions for iRhythm Technologies. Tandem Diabetes Care's average media sentiment score of 1.45 beat iRhythm Technologies' score of 1.00 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation & earnings, IRTC or TNDM?

iRhythm Technologies has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$492.68M	5.57	-$123.41M	-$4.23	-20.85
Tandem Diabetes Care	$770.01M	4.30	-$222.61M	-$2.17	-23.61

Does the MarketBeat Community believe in IRTC or TNDM?

Tandem Diabetes Care received 183 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.04% of users gave iRhythm Technologies an outperform vote while only 61.18% of users gave Tandem Diabetes Care an outperform vote.

Company	Underperform	Outperform
iRhythm Technologies	Outperform Votes 389 66.04%	Underperform Votes 200 33.96%
Tandem Diabetes Care	Outperform Votes 572 61.18%	Underperform Votes 363 38.82%

Summary

iRhythm Technologies and Tandem Diabetes Care tied by winning 8 of the 16 factors compared between the two stocks.